Gene Therapy Deals Up 1700% in 2026 — Here's the Data

36 gene therapy deals closed between March and September 2026 — a 1700% increase over the prior six-month period, which logged exactly 2. This is not a statistical quirk or a rounding artifact. Gene therapy licensing 2026 activity reflects a structural shift: large-cap pharma has collectively decided that in vivo gene correction is no longer a speculative bet but a pipeline necessity, and they're paying accordingly.

The Data — Gene Therapy Deal Activity, Period over Period

The baseline period — September 2025 through early March 2026 — was unusually quiet, even by gene therapy standards. That lull made the subsequent rebound look even more dramatic, but the absolute number of 36 deals in six months is itself remarkable. For context, DealForma tracked roughly 40–50 gene therapy transactions across all of 2024. We're on pace to triple that annualized run rate.

What's Driving the Trend

Three forces converged to produce this surge, and none of them are temporary.

First, manufacturing maturation. The single biggest knock against gene therapy for the last decade — cost of goods and manufacturing scalability — has materially improved. AAV production yields have roughly doubled since 2023 at several major CDMOs, and next-generation capsids are enabling lower dosing. This changes the commercial math. Therapies that looked uneconomical at $2M+ per patient start to pencil out at $800K–$1.2M with improved manufacturing, particularly for larger patient populations in cardiology and metabolic disease. That unlocks deal structures that weren't viable two years ago.

Second, FDA regulatory clarity. The agency's updated guidance on long-term follow-up requirements for gene therapies, finalized in late 2025, reduced one of the largest sources of uncertainty for acquirers. Sponsors now have a clearer framework for post-market commitments, which directly impacts NPV models and, by extension, what buyers are willing to pay upfront. The approval of several gene therapies in rare disease through 2025 also established a regulatory track record that de-risks the modality for BD teams building diligence packages.

Third, Big Pharma pipeline anxiety. Lilly, AbbVie, Roche, and Novartis collectively face $80B+ in revenue exposed to LOE between 2027 and 2031. Gene therapy — with its potential for durable, one-time curative treatments and orphan drug exclusivity — offers a differentiated growth vector that GLP-1s and ADCs alone cannot fill. The competitive pressure is real: once Lilly moved on Verve, every other large-cap cardiovascular and metabolic franchise had to reassess its gene therapy strategy within weeks. This is the cascading effect you see in gene therapy deal trends 2026.

Notable Deals

The Verve-Lilly deal is the headline. A $1B upfront with $2.3B in total deal value for a gene editing approach to PCSK9 — targeting cardiovascular disease with a one-time treatment. This is Lilly signaling that gene therapy isn't just for ultra-rare diseases anymore. The upfront alone is larger than most entire gene therapy company valuations two years ago. It resets the comp table for every cardio-metabolic gene therapy asset in development. If you're running a BD process for a gene therapy asset with Phase I/II data in a large indication, the Verve deal is your anchor point. Use it. Reference our Deal Benchmarks for comparable structures.

The REGENXBIO-AbbVie partnership is notable for what it represents strategically rather than financially (terms were not disclosed). REGENXBIO's NAV Technology Platform — its proprietary AAV capsid library — is one of the most broadly licensed delivery platforms in the field. AbbVie's decision to partner here suggests the company is building foundational gene therapy capabilities, not just acquiring individual programs. This is a platform play, and it signals AbbVie's intent to compete across multiple gene therapy indications over the next decade.

Lilly's dual Engage Bio deals — $202M and $200M in TDV, closed one day apart — look like a rapid land-grab for delivery technology or complementary programs. Two deals with the same licensor in 48 hours is unusual and suggests Lilly had pre-negotiated a broader package. For smaller biotechs, this is a signal: Lilly's gene therapy BD team is moving fast and willing to structure multi-asset transactions.

The MeiraGTx-Oberland Capital deal stands out because it involves a non-traditional buyer. Oberland is a royalty and structured capital firm, not a pharma company. A $400M TDV commitment from a financial investor validates that gene therapy cash flows are becoming predictable enough to attract capital beyond strategic acquirers. This expands the buyer universe for gene therapy licensors and creates competitive tension in deal processes — exactly the dynamic that drives valuations higher.

What This Means for BD Teams Right Now

If you're selling: This is a seller's market, full stop. The combination of Big Pharma urgency, compressed timelines, and multiple credible bidders (including financial buyers like Oberland) gives licensors meaningful leverage. Gene therapy licensing 2026 valuations are resetting upward — the Verve deal proves that $1B upfronts are achievable for clinical-stage assets in large indications. Even preclinical platforms are commanding $150M–$400M TDVs, as the Engage Bio and MeiraGTx deals demonstrate. Run a competitive process. Do not accept the first term sheet.

If you're buying: Move now, but structure carefully. The window where gene therapy assets traded at orphan-disease-discount multiples is closed. Every major pharma company with LOE exposure is looking at the same target list. Waiting six months means paying more or losing access entirely. That said, deal structures are evolving in ways that protect buyers: milestone-heavy structures with 25–35% upfront-to-TDV ratios are becoming standard (the Verve deal was approximately 43%, which is rich). Manufacturing risk-sharing provisions and opt-in rights at clinical milestones are gaining favor. Use Solidus to stress-test your valuation assumptions against current market comps before entering negotiations.

On structure: Royalty monetization deals like MeiraGTx-Oberland are gaining traction as an alternative to traditional licensing. For biotechs that want to retain program control but need capital, structured royalty transactions offer a non-dilutive path. Expect more of these in H2 2026, particularly for assets with near-term approval catalysts. For pharma BD teams, this means your competition for assets now includes financial investors with different return thresholds and faster decision-making processes.

Benchmark your deal against current market rates. Gene therapy deal trends 2026 have moved fast enough that comps from even six months ago are stale. Use the Ambrosia calculator to pressure-test your upfront, milestones, and royalty structures against the latest closed transactions before your next negotiation.